Preclinical studies have demonstrated that vascular endothelial growth factor (VEGF) inhibition can transiently normalize tumor vasculature, thereby improving perfusion, enhancing oxygenation, and reducing interstitial fluid pressure—all of which can sensitize tumors to RT. This evidence concerns the gene VEGFA and neoplasm.